Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Solvay will acquire Innogenetics for about $280 million, a 53% premium to the diagnostics company's stock market value before the deal was announced. Solvay already owns a 7% stake in Innogenetics, purchased when the two Belgian companies formed an R&D pact in 1997. Solvay says it will preserve the autonomy of Innogenetics, which recently decided to focus on diagnostics and divest its GENimmune immune therapeutics subsidiary. Solvay says the purchase will help it develop therapeutics by using biomarker and diagnostics technologies.
This article has been sent to the following recipient: